跳至主要内容
临床试验/NCT06655493
NCT06655493已完成不适用

A Cross-sectional Study to Investigate Prevalence of Systemic Inflammation (hsCRP) in Cohort of Patients With HF and a Cohort of Patients With ASCVD and CKD in the Middle East

Novo Nordisk A/S20 个研究点 分布在 2 个国家目标入组 756 人开始时间: 2024年11月22日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
756
试验地点
20
主要终点
High Sensitivity C-Reactive Protein (hsCRP) ≥2 mg/L

研究概览

简要总结

This study will collect medical and background information from participants with diseases that affect the heart and blood vessels (cardiovascular disease) with/without kidney disease.

The aim of the study is to assess the number of people with high levels of systemic inflammation among Middle East people with cardiovascular with/without kidney disease. Systemic inflammation means that it occurs throughout the body.

Participation in this study only requires a single visit at the clinic/hospital/medical institution. Participants will continue their normal care and will not get any treatment as part of this study.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
  • Male or female, age above or equal to 18 years at the time of signing informed consent.
  • Diagnosed with ASCVD+CKD and/or HF (pEF or mrEF)

排除标准

  • Previous participation in this study. Participation is defined as having given informed consent in this study.
  • Current participation (i.e., signed informed consent) in any other interventional clinical study.
  • Any hospitalization or unplanned visit within the last 60 days (including exacerbation of chronic disease with hospitalization).
  • Clinical evidence, or suspicion of, active infection within the last 60 days.
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

结局指标

主要结局

High Sensitivity C-Reactive Protein (hsCRP) ≥2 mg/L

时间窗: At Visit (day 0)

Count of patients

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (20)

Loading locations...

相似试验

Levels of Inflammation in Middle East People With... | 临床试验